Neuphoria Therapeutics Faces Delisting Notice
Ticker: NEUP · Form: 8-K · Filed: Jul 18, 2025 · CIK: 1191070
| Field | Detail |
|---|---|
| Company | Neuphoria Therapeutics Inc. (NEUP) |
| Form Type | 8-K |
| Filed Date | Jul 18, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Neuphoria Therapeutics got a delisting warning from the SEC.
AI Summary
Neuphoria Therapeutics Inc. filed an 8-K on July 18, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Bionomics Limited/FI, is incorporated in Delaware and has its principal executive offices in Burlington, Massachusetts.
Why It Matters
This filing indicates potential issues with Neuphoria Therapeutics' continued listing on an exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operational viability and stock price.
Key Players & Entities
- Neuphoria Therapeutics Inc. (company) — Registrant
- BIONOMICS LIMITED/FI (company) — Former company name
- July 18, 2025 (date) — Date of report
- Burlington, Massachusetts (location) — Principal executive offices
FAQ
What specific listing rule or standard has Neuphoria Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Neuphoria Therapeutics has failed to satisfy, only that a notice has been issued.
What is the potential consequence of failing to satisfy the listing rule?
The filing indicates a potential for delisting or transfer of listing, which could negatively impact the company's stock.
When was Neuphoria Therapeutics formerly known as?
Neuphoria Therapeutics was formerly known as BIONOMICS LIMITED/FI.
Where are Neuphoria Therapeutics' principal executive offices located?
Neuphoria Therapeutics' principal executive offices are located at 100 Summit Dr, Burlington, Massachusetts 01803.
What is the filing date of this Current Report?
The filing date of this Current Report is July 18, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 18, 2025 regarding Neuphoria Therapeutics Inc. (NEUP).